Detailed company information
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 12, 2026
Earnings Transcript for 2026 - Q1Released: May 12, 2026
Earnings Transcript for 2025 - Q4Released: Mar 05, 2026
Earnings Transcript for 2025 - Q3Released: Nov 04, 2025
Earnings Transcript for 2025 - Q2Released: Aug 09, 2025
Earnings Transcript for 2025 - Q1Released: May 01, 2025
Earnings Transcript for 2024 - Q4Released: Feb 27, 2025
Earnings Transcript for 2024 - Q3Released: Nov 09, 2024
Earnings Transcript for 2024 - Q2Released: Aug 09, 2024
Earnings Transcript for 2024 - Q1Released: May 02, 2024
Earnings Transcript for 2023 - Q4Released: Feb 27, 2024
Earnings Transcript for 2023 - Q3Released: Nov 03, 2023
Earnings Transcript for 2023 - Q2Released: Aug 06, 2023
Earnings Transcript for 2023 - Q1Released: May 10, 2023
Earnings Transcript for 2022 - Q4Released: Feb 23, 2023
Earnings Transcript for 2022 - Q3Released: Nov 05, 2022
Earnings Transcript for 2022 - Q2Released: Aug 03, 2022
Earnings Transcript for 2022 - Q1Released: May 04, 2022
Earnings Transcript for 2021 - Q4Released: Feb 24, 2022
Earnings Transcript for 2021 - Q3Released: Nov 07, 2021
Earnings Transcript for 2021 - Q2Released: Aug 07, 2021
Earnings Transcript for 2021 - Q1Released: May 09, 2021
Earnings Transcript for 2020 - Q4Released: Feb 24, 2021
Earnings Transcript for 2020 - Q3Released: Nov 07, 2020
ERAS Erasca, Inc.
💡 Across Q2 2025 earnings calls, companies reveal key pain points ideal for lightweight software solutions 🛠️ like workflow automation, AI tools, and dashboards, enabling quick wins with high impact across industries.
Read post
Dafinchi
